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Abstract
Background: Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality worldwide, but
few studies have evaluated the feasibility of routine patient-reported outcome measures (PROMs) in this illness. This
study investigates the feasibility and limitations of three credible PROM instruments in a representative hospitalized
cohort to identify potential barriers to routine application.
Methods: A sample of multimorbid hospitalized subjects meeting a standardized CAP definition was recruited.
Demographic and clinical data of those able and unable to participate in PROM assessment were compared.
The EQ-5D-5L, CAP-Sym 18 Questionnaire, and Late-Life Function and Disability Instrument (LLFDI) were
administered (via face-to-face interview) at admission and discharge and (via phone interview or mail) at 30
and 90 days post-discharge. Feasibility measures included the proportion of individuals able to participate in
assessment, attrition rates, data completeness, and instrument completion times. Scores at admission and 30
days post-discharge were examined for association with age.
Results: Of 82 subjects screened, 44 (54%) participated. Cognitive impairment (n = 12, 15%) commonly
precluded participation. Seventeen (39%) participants were lost to follow-up by 90 days. Missing data at item
level was negligible for all instruments, regardless of the mode of completion. Completion of the three
instruments collectively in a face-to-face interview took a median of 17 min (IQ range 13–21) per participant.
The burden of reported symptoms at admission was higher for younger participants aged 18–74 years (mean
(standard deviation)) CAP-Sym 18 score at admission 34.2 (18.6) vs. 19.0 (11.3) for those aged ≥ 75 years.
Conclusions: Routine application of PROMs can provide valuable information relating to multiple aspects of
clinical recovery for individuals hospitalized with CAP. However, heterogeneous demographic characteristics
and complex underlying health status introduce challenges to feasibility and interpretability of these
instruments in this population.
Trial registration: ClinicalTrials.gov, NCT02835040.
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Background
Community-acquired pneumonia (CAP) is not only a
common cause of death in Australia [1], but also the
third leading contributor to lost disability-adjusted life
years worldwide, especially in the elderly population [2].
While it is often expected that patients with CAP will
return to their pre-pneumonia baseline within a short
period of time [3], many continue to suffer from signifi-
cant deconditioning and loss of functional independence
and wellbeing long after diagnosis [4, 5]. Misunderstand-
ing of recovery may in part be due to the common out-
come measures used to ascertain the effectiveness of
treatment responses, such as time to clinical stability,
adverse events, readmissions, and hospital length of stay
[6–10], which largely support the interests of health
providers rather than patients [11]. Consideration of pa-
tient-reported outcomes is vital to evaluate the impact of
CAP on an individual’s perception of their wellbeing and
function [12, 13]. This in return provides valuable infor-
mation to health providers regarding how they can fur-
ther improve treatment effectiveness and service delivery
[11].
Developing a single PROM specific to CAP which en-
compasses all relevant patient-centered constructs is
challenging due to the multisystem nature of the illness
which, in addition to its impact on the respiratory or-
gans, also frequently leads to the development of car-
diac, gastrointestinal, and neurological complications
[14, 15]. While popular generic PROMs, such as the EQ-
5D-5L [16] can be used for people with CAP, these tools
do not take into account disease-specific symptoms.
Conversely, while existing disease-specific PROMs for
CAP measure a broad range of symptoms relevant to
the illness, they fail to consider the impact of existing
co-morbidities in individuals with CAP [12, 17, 18],
thereby perpetuating fragmented disease-centric, rather
than person-centric, care [19]. Consideration of under-
lying chronic disease is particularly important due to the
prevalence of CAP among older people, many of whom
have pre-existing co-morbidities [20–22]. The use of a
“modular” approach to PROMs [23], where an individu-
alized combination of multiple short instruments is se-
lected, may be useful to address the shortcomings of
utilizing only a single disease-specific tool to capture all
relevant aspects of patient recovery [12, 24]. This would
allow consistent large-sample measurement of outcomes
relevant to all patient groups, such as physical function
and quality of life, using generic instruments, in addition
to highly specific symptom scores tailored to one or
multiple conditions as relevant.
While the use of PROMs provides valuable informa-
tion about the impact of disease from the patient’s per-
spective, the limited uptake of PROMs in current CAP
literature suggests potential challenges to their feasibility
in this patient group. Resource limitations, including
staff time required to perform assessments, and impedi-
ments to patient participation, such as sick, elderly
patients unable or reluctant to complete survey instru-
ments, may result in incomplete and biased data collec-
tion [25]. Advocates of the use of PROMs in CAP
research have provided limited guidance regarding their
practical application in representative patient cohorts
[13, 24, 26], and feasibility of implementation needs fur-
ther exploration. Additionally, all CAP-specific PROM
instruments developed to date have been validated in
population samples with a mean age under 70 years
[17, 18, 27, 28], which raises questions regarding the
generalizability of published statistical distributions of
scores. This study therefore sought to examine the
feasibility of routinely implementing three short
PROM instruments (consistent with the “modular”
approach presented above), each addressing a separate
aspect of patient recovery: health-related quality of
life (EQ-5D-5L English instrument [16]), physical
function (Late-Life Function and Disability Instrument
(LLFDI) [29]), and symptoms specifically related to
CAP (CAP-Sym Questionnaire [17]). As none of these
instruments have been explicitly validated in elderly
hospitalized CAP populations, the data collected were
examined to identify inconsistencies that may under-
mine interpretation of these instruments in the target
patient group and prompt a need for further psycho-
metric testing before integrating their use into routine
practice.
Methods
Study design, setting, and participants
This prospective observational study was conducted at a
tertiary metropolitan teaching hospital campus serving a
population of approximately 700,000 in the western sub-
urbs of Melbourne, Australia. This region has Australia’s
highest proportion of non-English speaking migrants,
with 58.4% of individuals speaking a language other than
English at home [30]. Participants were prospectively re-
cruited over 10 weeks between October and December
2016, as a nested “study within a trial” (SWAT) analysis
for a larger study described elsewhere (trial registration:
ClinicalTrials.gov, NCT02835040) [31].
All consecutive subjects hospitalized under general in-
ternal medicine units (managing the majority of adult
CAP) who met a standardized definition of CAP [32],
and were being actively treated, were screened for their
ability to participate in PROM assessments. The follow-
ing exclusion criteria were applied: (a) acute or chronic
cognitive impairment impeding ability to provide in-
formed consent, either documented in the subject’s med-
ical record or based on clinical assessment by the
treating medical team, (b) impaired conscious state, (c)
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receiving continuous ventilatory support, and (d) requir-
ing language interpretation with medical assessments.
Given the diversity of language backgrounds in the tar-
get population, and limitations on the availability of pro-
fessional interpreting resources, cost constraints for this
study meant that only English language assessments
were conducted with data collected on language back-
grounds to inform future work. Written informed con-
sent was obtained from all individual participants.
Instruments selected for pilot testing
The EQ-5D-5L is a simple questionnaire that allows
an individual to rate their quality of life in the follow-
ing five dimensions: mobility, self-care, usual activ-
ities, pain/discomfort, and anxiety/depression; with
participants asked to rate each dimension on a five
point scale [33]. The rating given to each dimension
is later combined into a 5-digit number that describes
the respondent’s health status. While yet to be vali-
dated specifically for individuals with CAP, the EQ-
5D-5L has proven to be a valid and useful tool in ap-
praising recovery, treatment response, and cost-effect-
iveness across multiple disease states [34, 35]. The
UK utility index values and algorithm for health-re-
lated quality of life were used [36].
The LLFDI is an outcome measure that was specifically
developed for community-dwelling older adults (age > 60
years) [29], has been validated in elderly inpatient popula-
tions [37], and the 32-item function component provides
a self-report alternative to performance-based measures of
function [38]. The “advanced lower limb” sub-score in
particular has shown a high correlation with the perform-
ance of functional endurance tests [29]. Utilizing a 5-point
scale, where “5 = no difficulty” while “1=cannot do the task
at all,” participants were asked to rate their perceived level
of difficulty in completing various tasks, with scores for all
items aggregated and converted to a standardized scale
[38]. Physical de-conditioning in elderly individuals (espe-
cially those hospitalized) is likely to be a major contributor
to mortality and healthcare burden from CAP [39]. The
LLFDI was chosen instead of other measures of depend-
ence in activities of daily living (e.g., the Barthel Index [39]
or Katz Index [5, 40], the function sub-score of the short
form-36 (SF-36) [41], performance-based physical tests
[42], or non-validated scores [15]) used in previous studies
in CAP as it does not share the same shortcomings, such
as ceiling effects, lack of specificity when function is the
outcome of interest, impracticality in the target popula-
tion, or a lack of credibility.
To augment the more generic EQ-5D-5L and LLFDI in-
struments, a CAP disease-specific tool was also sought.
Although several symptom severity scores have been de-
veloped for and validated in CAP populations [17, 18, 27],
the CAP-Sym Questionnaire was selected due to its
brevity, clear and simple framework, and consistency with
the 5-point rating scale design utilized in the EQ-5D-5L
and LLFDI. The CAP-Sym has been validated in a large
sample of individuals with CAP and is more responsive
than the generic SF-36 [17].
All instruments, including scoring frameworks, were
used in accordance with instructions from the instru-
ment developers, and none were modified in any way.
This meant that only the LLFDI could be used to
quantify any aspects of pre-pneumonia health status,
in this case, physical function, as both the EQ-5D-5L
and CAP-Sym Questionnaire are designed to be rated
only on the day of completion. Only English language
versions of each instrument were used.
Feasibility outcomes
Feasibility of the chosen instruments was assessed ac-
cording to the following pre-specified measures.
1. Ability to participate in questionnaire-based
assessment, as measured by the following:
(a) Proportion willing and able to participate in the
study in comparison to a recent large
observational cohort benchmark (where
recovery from CAP was assessed using PROMs
as the primary outcome) of 32% [4]
(b) Proportion meeting each individual exclusion
criteria;
2. Missing data, measured by the following:
(a) Participant attrition at each time-point during
follow-up
(b) Proportion of items marked incomplete in over
5% of questionnaire attempts [27]
3. Ease of use, measured by the following:
(a) Time taken to complete each instrument face-
to-face and via telephone
(b) Reasons given by subjects or clinicians for
difficulty or non-completion
4. Floor and ceiling effects calculated as percentage of
participants recording the highest or lowest score
on the scale—this value should not exceed 15%
[43].
Measures of central tendency and variance for the
obtained scores were compared between younger (18–
74 years) and older (≥ 75 years) subjects to explore
trends that may impact on the interpretation of
scores from different age groups. The CAP-Sym and
EQ-5D scores were compared between groups at ad-
mission to hospital and to measure recovery from ad-
mission to 90 days post-discharge. The LLFDI total
and advanced lower limb scores were used to com-
pare functional status pre-pneumonia to 30 days post-
discharge.
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Data collection and management
Study data were collected and managed using RED-
Cap electronic data capture tools [44] hosted at The
University of Melbourne. Subjects were invited to par-
ticipate in PROM assessments at four time points: ad-
mission to the ward, discharge from acute hospital
stay, and 30 and 90 days post-discharge. Demographic
and clinical data (age, sex, language status, residential
status, comorbidities, and disease severity) were avail-
able for all CAP patients admitted during the SWAT
analysis recruitment period via the main trial data-
base. These data were used to identify differences in
the characteristics of those individuals participating in
the PROM feasibility study compared to those who
did not. The EQ-5D-5L and CAP-Sym were com-
pleted at each time point. The LLFDI was completed
at admission, where participants were asked to reflect
on their functional performance on a typical day in
the weeks prior to admission to hospital, and at 30
days post-discharge. Admission and discharge mea-
sures were completed in the hospital through face-to-
face interview with a study investigator. Admission
assessments were completed on the first day of hos-
pital admission and discharge assessments on the last
day of stay on the acute ward (i.e., immediately prior
to discharge either home or to an interim sub-acute
rehabilitation facility). Post-discharge PROMs were
assessed verbally via phone. If participants were un-
able to be contacted by phone for five consecutive
business days, or if they requested to complete ques-
tionnaires independently, copies of instruments were
provided via post. If forms were not returned to the
study coordinator within 30 days of posting, the par-
ticipant was considered lost to follow-up for post-dis-
charge outcomes.
Statistical analysis
Descriptive statistics are reported as mean (standard de-
viation (SD)) or median (inter-quartile range (IQR)) for
normally and non-normally distributed continuous vari-
ables, respectively, and counts (percentages) for categor-
ical variables. Statistical analyses were completed using
Stata version 14.2 (StataCorp, College Station, Texas,
USA).
Results
Of the 82 CAP patients admitted during the recruitment
period, 24 (29%) were unable to participate most com-
monly due to either limited English (n = 17, 21%) and/or
cognitive impairment (n = 12, 15%), and a further 14
(17%) declined to participate (Fig. 1). All 44 participants
successfully completed required inpatient assessments,
with 10 (23%) and 17 (39%) lost to follow-up at 30 and
90 days, respectively.
Subjects who participated in PROM assessments were
more likely to be younger (median age 73.5 [IQR 63.0–
80.0] vs. 77.0 [IQR 72.0–84.0] years for non-partici-
pants), living independently in the community (91% vs.
82%), and able to walk independently (98% vs. 79%)
(Table 1). As expected given study exclusion criteria,
non-participants had a higher proportion of diagnosed
dementia (18% vs. 2%) and acute confusion (26% vs. 2%),
admission to intensive care (11% vs. 0%), and a non-Eng-
lish primary language (47% vs. 11%) compared to those
that participated.
The CAP-Sym and EQ-5D-5L Questionnaires had the
shortest completion times (face-to-face median [IQR] 4
[2.5–5] and 3 [2–5] min, respectively) while the LLFDI
contains a larger number of items and therefore took
longer to complete (10 [6–11] min) (Table 2). A face-to-
face assessment requiring completion of all three mea-
sures took an aggregate median of 17 min [IQR 13–21],
and there was very little difference compared to comple-
tion via telephone (16 min [IQR 12–20]). Missing data
at instrument level only influenced assessments com-
pleted via phone or mail (Table 2), primarily due to an
inability to contact, or non-response of participants. At
item level, missing data were negligible for all instru-
ments. Hearing impairment, subject unavailability due to
ongoing ill health, and poor recall were common diffi-
culties reported by research assistants during the PROM
assessments. Only the EQ-5D-5L utility index displayed
ceiling effects outside the acceptable 15% range.
There was a trend for younger participants (aged 18–
74 years) to report a higher burden of symptoms at ad-
mission when compared to those aged ≥ 75 (mean (SD)
CAP-Sym 18 admission score 34.2 (18.6) vs. 19.0 (11.3)).
(Table 3 and Fig. 2). At discharge, the burden of symp-
toms had reduced for both age groups (CAP-Sym 18 dis-
charge score for those aged 18–74 years 21.1 (11.3) and
≥ 75 years 14.3 (10.2)). There was a small decrease in the
ability to perform functional endurance tasks at 30 days
for participants aged ≥ 60 years (LLFDI advanced lower
limb score median [IQR] 33.1 [27.7–47.8] pre-morbid
vs. 33.1 [11.35–47.8] 30 days).
Discussion
The results of this study highlight some of the chal-
lenges of administering PROMs to patients hospitalized
for CAP and may explain why the utilization of PROMs,
particularly as primary end-points, has remained limited
in CAP research. Language barriers, impaired cognition,
and severity of illness resulted in the exclusion of 29% of
the total subjects admitted with CAP during the study
period from PROM assessment. Additionally, hearing
and visual impairment complicated the participant con-
sent and PROM assessment process in a number of
cases. While the CAP-Sym, LLFDI, and EQ-5D-5L are
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currently available in 13, 3, and 150 language versions,
respectively, the feasibility of these PROMs has yet to be
tested among populations from diverse cultural back-
grounds. Significant interpreting resources will be re-
quired to facilitate the utilization of PROMs in health
settings similar to ours.
Other than language difficulties, acute and chronic
cognitive impairment also posed another challenge in
administering PROMs in the hospital setting. While the
self-reported quality of life instruments developed
specifically for dementia have shown promise [45], self-
report is not always viable for those with cognitive
impairment, and other available options for outcome
measurement must be considered for this group. This
also applies to the use of PROMs in individuals with
acute illness leading to impaired conscious state or other
severe symptoms that impede the ability to participate in
the questionnaire-based assessment. Time constraints
and concentration span hinder the completion of long
or multiple questionnaires, forcing researchers and clini-
cians to prioritize the types of information that is
sought. In our study, while the individual PROM ques-
tionnaires were completed quickly, in aggregate, the
three instruments took over 15 min in the majority of
subjects, emphasizing the resource-intensive nature of
this type of outcome measure.
Challenges in conducting a longitudinal cohort study to
monitor changes in PROMs have also been identified in
this study. Despite concerted efforts to follow-up partici-
pants via both phone and mail, subject attrition was
around 40% at 90 days. This attrition rate, though not un-
precedented [46], is higher than other large observational
studies in CAP [4] and may be a direct result of the study’s
inclusive recruitment strategy. Routine follow-up post-dis-
charge is difficult in this population due to inherent chal-
lenges associated with ongoing illness in the frail elderly
and the increased dependence on others for care. While
representative recruitment enables the generalization of
results to a broader population, a risk of higher participant
attrition during longitudinal follow-up is a trade-off that
must be considered. Providing flexible options for mode
of completion to maximize longitudinal participation must
be balanced against the risk of bias introduced by different
modes [47]. Future research could consider alternative
methods to reduce attrition, such as facilitation via a
family member, carer or primary care clinician, or the use
of technology to provide reminders and internet-based
options for instrument completion.
Fig. 1 Subject flow through the study. More than one reason for ineligibility may apply to a single participant; hence, the tally does not total 24.
Abbreviations: CAP community-acquired pneumonia, NESB non-English speaking background, PROMs patient-reported outcome measures
Lloyd et al. Pilot and Feasibility Studies            (2019) 5:97 Page 5 of 10
Table 1 Baseline characteristics, disease severity, and recovery of patients presenting with CAP: October–December 2016
Consenting participants* Declined participation or excluded*
(n = 44) (n = 38)
Demographics Age (years) 73.5 [63.0–80.0] 77 [72.0–84.0]
Males 23 (52.3%) 23 (60.1%)
NESB 5 (11.4%) 18 (47.4%)
Aged care resident 4 (9.1%) 7 (18.4%)
Lives alone 3 (6.8%) 10 (26.3%)
Premorbid health status CCMI ≥ 7 14 (31.8%) 15 (39.5%)
Anxiety/depression 7 (15.9%) 7 (18.4%)
Chronic pulmonary disease 26 (59.1%) 18 (47.4%)
CCF 9 (20.5%) 9 (23.7%)
Diabetes 16 (36.4%) 16 (42.1%)
Dementia 1 (2.2%) 7 (18.4%)
Malnutrition (MST score ≥ 2) 11 (25.0%) 15 (39.4%)
Walks without assistance† 43 (97.7%) 30 (78.9%)
Disease severity and complications CURB-65‡ ≥ 3 19 (43.2%) 19 (50.0%)
ICU admission 0 (0%) 4 (10.5%)
Acute cardiac event 5 (11.4%) 8 (21.1%)
Exacerbation CCF 7 (15.9%) 5 (13.2%)
Acute confusion 1 (2.2%) 10 (26.3%)
Recovery LOS (days) 4 [3–5] 4 [3–6]
30-day readmission 3 (6.8%) 6 (15.8%)
In hospital mortality 0 (0%) 1 (2.6%)
Death within 30 days 1 (2.3%) 3 (7.9%)
Abbreviations: CAP community-acquired pneumonia, CCF congestive cardiac failure, CCMI Charlson Comorbidity Index, LOS length of hospital stay, MST score
Malnutrition Screening Tool, NESB non-English speaking background (patient may or may not also be proficient in English)
*All data presented are median (interquartile range) or count (percentage)
†Walks without assistance: may use a gait aid but does not require the assistance of another person
‡CURB-65 score comprised of confusion, urea > 7mmol/L, respiratory rate ≥ 30 per minute, blood pressure < 90 mmHg systolic, ≤ 60 mmHg diastolic, and
age ≥ 65 years
Table 2 Patient-reported outcome measure completion time and missing data by instrument and mode of collection
EQ-5D LLFDI CAP-Sym 18
Completion time (minutes) (median, [IQ range]) Admission face-to-face (n = 44) 3 [2–5] 10 [6–11] 4 [2.5–5]
30-day phone (n = 34) 3 [2–5] 10 [7–13] 3 [2–5]
Missing data (n/N * (%)) Instrument level Face-to-face 0/87 (0%) 0/44 (0%) 0/87 (0%)
Phone 20/78 (25.6%) 10/44 (22.7%) 20/78 (25.6%)
Mail 12/20 (60.0%) 7/10 (70.0%) 14/20 (70.0%)
Item level†: No. of items with > 5%
missing values
Face-to-face 0/6 (0%) 0/32 (0%) 0/18 (0%)
Phone 0/6 (0%) 2/32 (6.25%) 0/18 (0%)
Mail 0/6 (0%) 0/32 (0%) 0/18 (0%)
Abbreviations: CAP-Sym 18 CAP-Symptom Questionnaire (18-item version), EQ-5D EuroQol Questionnaire, IQ interquartile, LLFDI Late Life Function and
Disability Instrument
*For instrument level data, the denominator represents the total number of occasions the instrument was attempted via that mode. Numbers differ between
instruments because the LLFDI was only completed on admission and at 30 days
†For item level data, the denominator represents the number of items in that instrument
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(mean (SD) or median (IQR))
≥ 75 years
(n = 21)
(mean (SD) or median (IQR))
CAP-Sym 18 score 34.2 (18.6) 19.0 (11.3)
EQ-5D VAS score 42.3 (18.8) 47.6 (21.3)
EQ-5D-5L index 0.54 [0.28–0.84] 0.68 [0.35–0.88]
Abbreviations: CAP-Sym 18 CAP-Sym Questionnaire 18-item score, CI confidence interval, EQ-5D VAS EuroQol Quality of Life Questionnaire visual analog score, EQ-
5D-5L index score EuroQol 5-dimension 5-level Questionnaire, IQR interquartile range, PROMs patient-reported outcome measure
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Fig. 2 Change in CAP-Sym 18 and EQ-5D visual analog scores over time according to age group. Instrument scoring (y-axis): CAP-Sym18 score:
CAP-Symptom Questionnaire score, consists of 18-items rated 0–5 where 0 has not experienced symptom and 5 extremely bothered by that
symptom, total possible score between 0 and 90; EQ-5D VAS score: EQ-5D-5L visual analog scale score, rated as 0–100 where 0 is the worst
health imaginable and 100 the best health imaginable. Time points (x-axis): ADM admission assessment conducted on first day of hospitalization,
DC discharge assessment conducted on day of discharge, 30: 30-day assessment conducted at 30-days post discharge, 90: 90-day assessment
conducted at 90 days post discharge
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Other than identifying the challenges faced when ad-
ministering PROMs, this study also highlighted import-
ant considerations to be taken when interpreting PROM
data in CAP populations. Consistent with previous
studies [18, 48], older individuals tended to report less
bothersome symptoms at admission and reported less
improvement 30 days after discharge. Possible reasons
for this trend include (i) younger individuals generally
need to be more symptomatic relative to elderly to be
hospitalized, whereas the threshold for admission in the
elderly may be much lower; (ii) age-related immunologic
changes may dampen systemic reactions to infection
such as fever and sweating [18], and (iii) older individ-
uals with chronic illness may be accustomed to poor
health meaning the marginal impact of an acute episode
is reduced. It is therefore possible that outcome scores
may be less responsive to change in elderly, multimorbid
cohorts due to the high burden of chronic illness. This
may also explain the lower CAP-Sym scores at admis-
sion reported in this study when compared to others
conducted in younger cohorts with less burden of
chronic disease [49, 50].
The results of this study also demonstrated that, for a
number of participants, endurance during physical tasks
was reduced even a month after discharge from hospital.
It may be hypothesized, based on results of this and
other studies [5, 51], that long-term ongoing decrease in
overall health status reported by CAP patients is linked
to fatigue and reduced endurance for activities of daily
living, rather than overall burden of symptoms which
appear to return quickly to baseline [3]. Further research
is required to fully investigate the role of impaired en-
durance in poor long-term outcomes from CAP and
identify effective interventions to address poor exercise
tolerance.
This study is the first study to the author’s knowledge
to investigate the feasibility of implementing PROMs for
patients hospitalized with CAP, though it has several im-
portant limitations. Due to the convenience sampling
approach employed within a larger trial, the overall sam-
ple size was small. Results of the analysis should there-
fore be considered exploratory, though they provide a
useful starting point for researchers considering applying
PROMs in hospitalized elderly populations. The limited
sample size was compounded by a lack of access to
interpreting services which precluded measurement of
PROM feasibility in patients from non-English speaking
backgrounds. Results of the study can therefore only be
generalized to English-speaking patient groups. Finally,
while levels of attrition were in themselves an interesting
outcome of this study, high numbers lost to follow-up
precluded statistical analysis of the 90-day outcomes due
to the risk of bias introduced by missing data in an
already small sample.
Conclusions
A modular approach to PROMs, comprising routine ap-
plication of three short instruments (EQ5D, LLFDI, and
CAP-Sym), can provide valuable information relating to
multiple aspects of clinical recovery for individuals hos-
pitalized with CAP. However, the heterogeneous charac-
teristics, acuity of illness, and complex underlying health
status of this population preclude the participation of a
significant proportion of individuals in PROM assess-
ment, introducing challenges to feasibility and interpret-
ability of these instruments. The exclusion of individuals
from diverse language backgrounds and with cognitive
impairment from PROM assessment is a particular con-
cern, and high rates of attrition also affected the feasibil-
ity of longitudinal assessment with these instruments.
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